DHI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
D.R. Horton is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has mixed sentiment and some constructive analyst support, but the current technical setup is weak, latest quarterly financials are declining year over year, and there is no Intellectia buy signal. If you need an immediate decision and are unwilling to wait for a better entry, I would not buy aggressively here; holding off is the better call.
DHI is trading at 145.38, below the pivot at 153.151 and just above first support at 144.982. The trend is currently bearish: MACD histogram is -1.277 and weakening, RSI_6 is 38.43, and the moving averages are stacked bearishly with SMA_200 > SMA_20 > SMA_5. That points to a downtrend or weak consolidation rather than a clean bullish entry. The short-term pattern model suggests a modest bounce probability, but the broader technical picture still favors caution.
Recent analyst target increases show improving expectations after Q2 earnings, with several firms lifting targets and multiple Buy ratings still in place from UBS, BTIG, and Goldman Sachs. Hedge funds are reportedly buying aggressively, with buying activity up sharply over the last quarter. The Q2 earnings beat and better-than-expected guidance also provide a near-term fundamental catalyst, and the stock pattern model suggests a possible short-term rebound.
The stock fell on the day and remains below key resistance with a bearish technical structure. Q2 financials were softer year over year, with revenue down 2.27%, net income down 20.05%, EPS down 13.18%, and gross margin down 8.24%. Options activity is bearish, with a 1.4 put-call ratio on open interest and 4.5 on volume. Several analysts remain only neutral, equal weight, hold, or underperform, and RBC explicitly warned about valuation and fading the rally. Congress trading is balanced, showing no strong politically influential accumulation signal.
Latest quarter: 2026/Q2. Revenue fell to $7.5581B, down 2.27% YoY. Net income dropped to $647.9M, down 20.05% YoY. EPS declined to $2.24, down 13.18% YoY. Gross margin also compressed to 22.83%, down 8.24% YoY. The company did beat on some measures and had a solid new-order trend, but the core quarterly growth profile is still under pressure.
Analyst sentiment is mixed but slightly constructive. Target prices were raised across several firms after the earnings beat, including Citi to $173, Truist to $150, UBS to $206, BTIG to $188, Goldman Sachs to $190, Wells Fargo to $170, Barclays to $140, and Keefe Bruyette to $175. However, ratings are split: some firms are bullish (UBS, BTIG, Goldman), while others remain Neutral/Equal Weight/Hold or Underperform (Citi Neutral, Truist Hold, RBC Underperform, Wells Equal Weight, Barclays Equal Weight, Keefe Market Perform). Net view: Wall Street acknowledges solid execution, but the consensus is not strongly bullish.
